CAPR - Capricor Therapeutics, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Capricor Therapeutics, Inc.

8840 Wilshire Boulevard
2nd Floor
Beverly Hills, CA 90211
United States

Full-time employees39

Key executives

NameTitlePayExercisedYear born
Dr. Frank LitvackExec. ChairmanN/AN/A1956
Dr. Linda MarbánCo-Founder, Pres, CEO & Director232.91kN/A1963
Ms. Karen G. KrasneyExec. VP, Gen. Counsel & Sec.260.38kN/A1953
Dr. Deborah D. AscheimChief Medical OfficerN/AN/A1965
Prof. Eduardo MarbánCo-Founder & Chairman of Scientific Advisory BoardN/AN/AN/A
Amounts are as of 31 December 2016, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. Its development stage drug candidates for cardiosphere-derived cells include CAP-1002 that is in Phase I/II clinical trial in subjects with DMD; and CAP-2003 that is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.

Corporate governance

Capricor Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.
By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes